Martin Smoragiewicz
Overview
Explore the profile of Martin Smoragiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1053
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rajeswaran K, Muzio K, Briones J, Lim-Fat M, Tseng C, Smoragiewicz M, et al.
J Clin Med
. 2022 Jul;
11(14).
PMID: 35887929
Brain metastases (BM) are perceived as a rare complication of prostate cancer associated with poor outcome. Due to limited published data, we conducted a literature review regarding incidence, clinical characteristics,...
12.
Forner D, Mok F, Verma N, Karam I, Goldstein D, Higgins K, et al.
Oral Oncol
. 2022 May;
130:105903.
PMID: 35569318
Objectives: Percutaneous endoscopic gastrostomy (PEG) placement is essential for the provision of enteral nutrition in select head and neck cancer (HNC) patients. Minimally invasive tube placement is facilitated through one...
13.
Wells J, Sidhu A, Ding K, Smoragiewicz M, Heng D, Shepherd F, et al.
Oncologist
. 2022 Mar;
27(3):e286-e293.
PMID: 35274718
Background: Complementary medicines (CM) are frequently used by patients with cancer. Controversy exists over the effectiveness and risk that CM may add to conventional cancer therapy. The incidence of CM...
14.
Parmar A, Timilshina N, Emmenegger U, Smoragiewicz M, Sander B, Alibhai S, et al.
Can Urol Assoc J
. 2021 Oct;
16(3):E126-E131.
PMID: 34672942
Introduction: Earlier application of oral androgen receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer (mCSPC) has established improvements in overall survival, as compared to androgen deprivation therapy (ADT) alone....
15.
Khalid S, Basulaiman B, Emack J, Booth C, Duran I, Robinson A, et al.
Eur Urol Open Sci
. 2021 Aug;
21:61-68.
PMID: 34337469
Background: Fibroblast growth factor receptor 3 (FGFR3) mutations have been implicated in urothelial tumorigenesis. FGFR3 inhibitors are being explored in clinical trials. Objective: We aimed to study the association between...
16.
Briones J, Khan M, Sidhu A, Zhang L, Smoragiewicz M, Emmenegger U
Front Oncol
. 2021 May;
11:658331.
PMID: 34026638
Background: Both Docetaxel (DOC) and Abiraterone (ABI) improve the survival of men with metastatic, castration sensitive prostate cancer (mCSPC). However, the outcome among mCSPC patients is highly variable, while there...
17.
18.
Biasci D, Smoragiewicz M, Connell C, Wang Z, Gao Y, Thaventhiran J, et al.
Proc Natl Acad Sci U S A
. 2020 Oct;
117(46):28960-28970.
PMID: 33127761
Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1 T cell checkpoint induces T cell infiltration and anticancer responses in murine and human pancreatic cancer. Here...
19.
Juergens R, Hao D, Ellis P, Tu D, Mates M, Kollmannsberger C, et al.
Lung Cancer
. 2020 Mar;
143:1-11.
PMID: 32169783
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab (Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy. Eligible patients were enrolled into...
20.
Smoragiewicz M, Adjei A, Calvo E, Tabernero J, Marabelle A, Massard C, et al.
Clin Cancer Res
. 2020 Feb;
26(11):2461-2465.
PMID: 32086344
Purpose: To review key aspects of the design and conduct of early clinical trials (ECT) of immunotherapy agents. Experimental Design: The Methodology for the Development of Innovative Cancer Therapies Task...